Primary immune thrombocytopenia needs to be "treated" according to the person, and the first-line, second-line, and third-line treatment methods are summarized here→

When it comes to primary immune thrombocytopenia (ITP), doctors and friends must be familiar with it, "at least 2 consecutive blood routine tests show a decrease in platelet count (< 100×10<b10>9/L) [^1]" The incidence is about (2~10)/100,000 people, and most of the people over 60 years old and women of childbearing age ^{[2, 3].
"]} "Physical examination can show skin ecchymosis or purpura, which is generally more common at the distal end of the limbs; Mucosal bleeding is more common with oral mucosal blood blisters, bleeding gums and nosebleeds" "In addition, other diseases that may cause thrombocytopenia need to be ruled out".
.
.

Doctors can judge the severity of ITP patients through platelet counts, and the treatment of ITP patients needs to be "treated"
from person to person.
Patients with platelet count ≥ 30×10⁹/L and no bleeding can be temporarily observed; Platelet count < 10x10<b12>9/L, or severe bleeding or risk of bleeding, should use high-dose hormones and other emergency treatment; In addition to the above conditions, other ITP patients need to gradually choose first-line, second-line, and third-line step therapy according to the treatment effect, and decide follow-up treatment or follow-up observation according to platelet recovery ^[1].

To learn more about primary immune thrombocytopenia, please click the figure below to enter the diagnosis and treatment knowledge base product of Yimaitong - "Medical Knowledge Source Disease Knowledge Base"
.
The knowledge of primary immune thrombocytopenia disease written by Dr.
Qi Jiaqian of the First Affiliated Hospital of Soochow University comprehensively shows the epidemiology, pathogenesis, diagnosis and treatment process, diagnostic criteria, treatment rules and drug treatment plan
of primary immune thrombocytopenia.